CENTRO DE INVESTIGACION DEL CANCER

  1. Concedido nuevo proyecto de investigación sobre tratamiento y diagnóstico de la Covid-19

    Actualidad

    Concedido nuevo proyecto de investigación sobre tratamiento y diagnóstico de la Covid-19

    READ MORE
  2. “Utiliza la fuerza”: un nuevo mecanismo que determina la migración y especialización celular a través del control de la textura

    Actualidad

    “Utiliza la fuerza”: un nuevo mecanismo que determina la migración y especialización celular a través del control de la textura

    READ MORE
  3. Nuevo proyecto para identificar factores de riesgo de infección grave e infectados por SARS-CoV-2

    Actualidad

    Nuevo proyecto para identificar factores de riesgo de infección grave e infectados por SARS-CoV-2

    READ MORE

    meetings

Papers

Leukemia Stem Cell Drug Discovery.
Cobaleda C, Sánchez-García I,
Methods Mol Biol;2021;2185();39-48;33165841

Leukemia Stem Cells: Concept and Implications.
Sánchez-García I, Cobaleda C,
Methods Mol Biol;2021;2185();25-37;33165840

The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities.
Nombela P, Miguel-López B, Blanco S,
Mol Cancer;2021;20(1);18;33461542

In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer.
Rojas K, Baliu-Piqué M, Manzano A, Saiz-Ladera C, García-Barberán V, Cimas FJ, Pérez-Segura P, Pandiella A, Győrffy B, Ocana A,
Cell Oncol (Dordr);2021;();10.1007/s13402-020-0;33469836

The human VRK1 chromatin kinase in cancer biology.
Campillo-Marcos I, García-González R, Navarro-Carrasco E, Lazo PA,
Cancer Lett;2021;503();117-128;33516791

Pathogenic convergence of CNVs in genes functionally associated to a severe neuromotor developmental delay syndrome.
García-Hernández JL, Corchete LA, Marcos-Alcalde I, Gómez-Puertas P, Fons C, Lazo PA,
Hum Genomics;2021;15(1);11;33557955

Infectious triggers and novel therapeutic opportunities in childhood B cell leukaemia.
Cobaleda C, Vicente-Dueñas C, Sánchez-García I,
Nat Rev Immunol;2021;();10.1038/s41577-021-0;33558682

An immune window of opportunity to prevent childhood B cell leukemia.
Cobaleda C, Vicente-Dueñas C, Sánchez-García I,
Trends Immunol;2021;();S1471-4906(21)00052-;33773925

Functional Specificity of the Members of the Sos Family of Ras-GEF Activators: Novel Role of Sos2 in Control of Epidermal Stem Cell Homeostasis.
Baltanás FC, Mucientes-Valdivieso C, Lorenzo-Martín LF, Fernández-Parejo N, García-Navas R, Segrelles C, Calzada N, Fuentes-Mateos R, Paramio JM, Bustelo XR, Santos E,
Cancers (Basel);2021;13(9);2152;33946974

Copy neutral loss of heterozygosity (cnLOH) patterns in synchronous colorectal cancer.
Tapial S, García JL, Corchete L, Holowatyj AN, Pérez J, Rueda D, Urioste M, González-Sarmiento R, Perea J,
Eur J Hum Genet;2021;29(4);709-713;33268847

Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy.
González M, Ovejero-Sánchez M, Vicente-Blázquez A, Alvarez R, Herrero AB, Medarde M, González-Sarmiento R, Peláez R,
Int J Mol Sci;2021;22(4);1907;33673002

A clinico-pathological and molecular analysis reveals differences between solitary (early and late-onset) and synchronous rectal cancer.
Perea J, García JL, Corchete L, Tapial S, Olmedillas-López S, Vivas A, García-Olmo D, Urioste M, Goel A, González-Sarmiento R,
Sci Rep;2021;11(1);2202;33500439

Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair.
Ovejero-Sánchez M, González-Sarmiento R, Herrero AB,
Neoplasia;2021;23(5);515-528;33930758

RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.
Sanclemente M, Nieto P, García-Alonso S, Fernández-García F, Esteban-Burgos L, Guerra C, Drosten M, Caleiras E, Martinez-Torrecuadrada J, Santamaría D, Musteanu M, Barbacid M,
Cancer Cell;2021;39(3);294-296;33513349

RASless MEFs as a Tool to Study RAS-Dependent and RAS-Independent Functions.
Lechuga CG, Salmón M, Paniagua G, Guerra C, Barbacid M, Drosten M,
Methods Mol Biol;2021;2262();335-346;33977488

last announcements

CONTRATO DE DOCTOR  PARA SU INCORPORACIÓN AL CIC SALAMANCA,  FINANCIADO POR EL PROYECTO AECC, “HACIA UNA MEDICINA PERSONALIZADA EN EL MIELOMA MÚLTIPLE (MM)

READ MORE

CONTRATO DE DOCTOR  PARA SU INCORPORACIÓN AL CIC SALAMANCA,  FINANCIADO POR EL PROYECTO AECC, “HACIA UNA MEDICINA PERSONALIZADA EN EL MIELOMA MÚLTIPLE (MM)

16/12/21

**OFFER DESCRIPTION: The position is associated to the research grant "Towards precision medicine in myeloma: search for predictive biomarkers, overcoming resistance and finding new therapeutic targets oriented to molecular subtypes", supported by the Scientific Foundation of the Spanish Association Against Cancer (AECC) for 2 years.

  • Required Education Level: PhD in biological sciences or biomedicine related fields.
  • Skills/Qualifications: Experience in cancer genomics and genome editing technologies, in particular. Preference will be given to individuals with a good publication record. Candidates will also be expected to aid in the supervision of junior lab members, to manage research projects, to prepare reports and papers for publication, and to contribute to grant writing.
  • Specific Requirements:

- Standard molecular and cellular biology techniques: cell cultures, plasmid manipulation, RT-PCR, etc.

- CRISPR knockout and CRISPR-Cas9 genome-wide screening approaches.

- Next generation sequencing techniques.

  • Required Languages: English and Spanish
  • Required Research Experience (years of research experience): 4-10 (since postdoc position).

TYPE OF CONTRACT : Temporary

JOB STATUS: Full-time

HOURS PER WEEK: 37.5

SALARY: 25.950 euros gross salary

ENVISAGED JOB STARTING DATE: February/March

OFFER STARTING DATE: December 16, 2021.

REFERENCE NUMBER: 21-26- HEMDOC

Apply for the job position  REF: 21-26-HEMDOC in  https:// www.cicancer.org, Job Offers.

DEADLINE:          January 31, 2022


Inscribirse DOWNLOAD PDF ×